Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 19

Results For "antibody"

553 News Found

Ichnos Glenmark Innovation receives USFDA fast track designation for ISB 2001 for relapsed/refractory multiple myeloma
News | May 06, 2025

Ichnos Glenmark Innovation receives USFDA fast track designation for ISB 2001 for relapsed/refractory multiple myeloma

IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma


Merck breaks ground on new $1 billion Biologics Center of Excellence in Delaware, US
News | April 29, 2025

Merck breaks ground on new $1 billion Biologics Center of Excellence in Delaware, US

Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA


Suven Pharmaceuticals get final approval to amalgamate Cohance Lifesciences
News | April 25, 2025

Suven Pharmaceuticals get final approval to amalgamate Cohance Lifesciences

The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations


Pfizer advances vision for future of cancer care at ASCO 2025 Annual Meeting
News | April 24, 2025

Pfizer advances vision for future of cancer care at ASCO 2025 Annual Meeting

Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs


GSK’s blenrep combinations approved by UK MHRA in relapsed/refractory multiple myeloma
News | April 19, 2025

GSK’s blenrep combinations approved by UK MHRA in relapsed/refractory multiple myeloma

Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed


Biocon Biologics announces USFDA approval for Jobevne biosimilar Bevacizumab
Drug Approval | April 11, 2025

Biocon Biologics announces USFDA approval for Jobevne biosimilar Bevacizumab

Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis


Asahi Kasei establishes Asahi Kasei Life Science to drive its bioprocess businesses
News | April 08, 2025

Asahi Kasei establishes Asahi Kasei Life Science to drive its bioprocess businesses

Asahi Kasei Life Science covers a broad range of bioprocess products and services


Asahi Kasei Life Science begins operation
News | April 03, 2025

Asahi Kasei Life Science begins operation

Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture


NCLT approves amalgamation of Cohance Lifesciences into and with Suven Pharmaceuticals
News | April 01, 2025

NCLT approves amalgamation of Cohance Lifesciences into and with Suven Pharmaceuticals

The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates


Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions
News | March 20, 2025

Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions

The new site will increase Syngene's total single-use bioreactor capacity to 50,000L